食管鳞状细胞癌的分子分型及相关分层因素

doi:10.3760/cma.j.cn371439-20200608-00116

摘要/Abstract

摘要：

利用传统的组织病理学特征对食管鳞状细胞癌(ESCC)进行分型用以指导临床治疗存在较大局限性,建立ESCC的分子分型是精准治疗/个性化治疗的必然要求。目前ESCC的分子分型尚未形成共识,也未在临床广泛应用。从蛋白质水平、基因多态性、DNA甲基化到非编码RNA等层面的分子标志物与ESCC的发生发展、治疗应答、预后等生物学行为密切相关,有望基于这些分子标志物建立ESCC的分子分型体系,从而更好地指导临床实践。

关键词: 食管肿瘤, 肿瘤, 鳞状细胞, 分子分类, 分子标志物

Abstract:

The use of traditional histopathological characteristics to classify esophageal squamous cell carcinoma (ESCC) has great limitations to guide clinical treatment. The establishment of molecular classification of ESCC is an inevitable requirement for precise treatment/personalized treatment. At present, the molecular classification of ESCC has not yet reached a consensus, nor has it been widely used in clinical practice. Many molecular markers ranging from protein level, gene polymorphism, DNA methylation to non-coding RNA are closely related to the occurrence, development, treatment response, prognosis and other biological behaviors of ESCC. It is expected to establish the molecular typing system of ESCC based on these molecular markers to better guide clinical practice.

Key words: Esophageal neoplasms, Neoplasms, squamous cell, Molecular typing, Molecular marker

项捷, 韩高华. 食管鳞状细胞癌的分子分型及相关分层因素[J]. 国际肿瘤学杂志, 2020, 47(12): 761-764.

Xiang Jie, Han Gaohua. Molecular typing and related stratification factors of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2020, 47(12): 761-764.

参考文献 30

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Xiong T, Wang M, Zhao J, et al. An esophageal squamous cell carcinoma classification system that reveals potential targets for therapy[J]. Oncotarget, 2017,8(30):49851-49860. DOI: 10.18632/oncotarget.17989. doi: 10.18632/oncotarget.17989 pmid: 28591712
[3]	Wang F, Yan Z, Lv J, et al. Gene expression profiling reveals distinct molecular subtypes of esophageal squamous cell carcinoma in Asian populations[J]. Neoplasia, 2019,21(6):571-581. DOI: 10.1016/j.neo.2019.03.013. doi: 10.1016/j.neo.2019.03.013 pmid: 31048097
[4]	唐裕福, 张怡冰, 冯晓东, 等. 14-3-3蛋白在人类疾病中的研究进展[J]. 世界华人消化杂志, 2017,25(6):509-520. DOI: 10.11569/wcjd.v25.i6.509.
[5]	Tong S, Chen SC, Xu KY, et al. 14-3-3ζ promotes esophageal squamous cell carcinoma invasion by repressing S1PR2 protein expression through NF-κB signaling[J]. Arch Biochem Biophys, 2018,643:7-13. DOI: 10.1016/j.abb.2018.02.009. doi: 10.1016/j.abb.2018.02.009 pmid: 29458005
[6]	Chen JY, Xu L, Fang WM, et al. Identification of PA28β as a potential novel biomarker in human esophageal squamous cell carcinoma[J]. Tumour Biol, 2017,39(10):1010428317719780. DOI: 10.1177/1010428317719780. doi: 10.1177/1010428317719780 pmid: 29020885
[7]	Zeng FM, He JZ, Wang SH, et al. A novel three-gene model predicts prognosis and therapeutic sensitivity in esophageal squamous cell carcinoma[J]. Biomed Res Int, 2019,2019:9828637. DOI: 10.1155/2019/9828637. doi: 10.1155/2019/9828637 pmid: 31886273
[8]	Luo H, Song H, Mao R, et al. Targeting valosin-containing protein enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma[J]. Cancer Sci, 2019,110(11):3464-3475. DOI: 10.1111/cas.14184. doi: 10.1111/cas.14184 pmid: 31454136
[9]	Qian Z, Wei B, Zhou Y, et al. PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma[J]. BMC Cancer, 2019,19(1):585. DOI: 10.1186/s12885-019-5818-7. doi: 10.1186/s12885-019-5818-7 pmid: 31200670
[10]	Peng H, Wang LG, Wang XZ, et al. The correlation between XIAP gene polymorphisms and esophageal squamous cell carcinoma susceptibility and prognosis in a Chinese population[J]. Pathol Res Pract, 2017,213(12):1482-1488. DOI: 10.1016/j.prp.2017.10.008. doi: 10.1016/j.prp.2017.10.008 pmid: 29037837
[11]	Qu Y, Zhang S, Cui L, et al. Two novel polymorphisms in PLCE1 are associated with the susceptibility to esophageal squamous cell carcinoma in Chinese population[J]. Dis Esophagus, 2017,30(1):1-7. DOI: 10.1111/dote.12463. doi: 10.1111/dote.12477 pmid: 26919257
[12]	Bulibu J, Wang W, Tang Y, et al. Association between polymorphisms in the promoter region of microRNA-34b/c and the chemo-radiotherapy efficacy for locally advanced esophageal squamous cell carcinoma in Chinese Han population[J]. Pathol Oncol Res, 2019,25(1):421-427. DOI: 10.1007/s12253-017-0366-4. doi: 10.1007/s12253-017-0366-4 pmid: 29270777
[13]	Yan T, Cui H, Zhou Y, et al. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma[J]. Nat Commun, 2019,10(1):1670. DOI: 10.1038/s41467-019-09255-1. doi: 10.1038/s41467-019-09255-1 pmid: 30975989
[14]	乔云, 胡晨曦, 宋大安, 等. 高通量靶向基因测序技术探查食管癌放射敏感性相关基因[J]. 中华肿瘤杂志, 2017,39(8):584-588. DOI: 10.3760/cma.j.issn.0253-3766.2017.08.005.
[15]	Wang YL, Yuan Y, Luo XX, et al. Genetic variants in EGFR/PLCE1 pathway are associated with prognosis of esophageal squamous cell carcinoma after radical resection[J]. Curr Med Sci, 2019,39(3):385-390. DOI: 10.1007/s11596-019-2047-x. doi: 10.1007/s11596-019-2047-x pmid: 31209807
[16]	Wang N, Li Y, Zhou RM, et al. The effect of polymorphisms in the promoter of the BIRC5 gene on the risk of oesophageal squamous cell carcinoma and patient's outcomes[J]. Mutagenesis, 2019,34(4):307-313. DOI: 10.1093/mutage/gez012. doi: 10.1093/mutage/gez012 pmid: 31165868
[17]	Xiong JX, Wang YS, Sheng J, et al. Epigenetic alterations of a novel antioxidant gene SLC22A3 predispose susceptible individuals to increased risk of esophageal cancer[J]. Int J Biol Sci, 2018,14(12):1658-1668. DOI: 10.7150/ijbs.28482. doi: 10.7150/ijbs.28482 pmid: 30416380
[18]	Kurimoto K, Hayashi M, Guerrero-Preston R, et al. PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma[J]. Epigenetics, 2017,12(10):865-874. DOI: 10.1080/15592294.2017.1365207. doi: 10.1080/15592294.2017.1365207 pmid: 29099287
[19]	Iwabu J, Yamashita S, Takeshima H, et al. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy[J]. Sci Rep, 2019,9(1):13347. DOI: 10.1038/s41598-019-50005-6. doi: 10.1038/s41598-019-50005-6 pmid: 31527639
[20]	Chen JL, Lin ZX, Qin YS, et al. Overexpression of long noncoding RNA LINC01419 in esophageal squamous cell carcinoma and its relation to the sensitivity to 5-fluorouracil by mediating GSTP1 methylation[J]. Ther Adv Med Oncol, 2019,11:1758835919838958. DOI: 10.1177/1758835919838958. doi: 10.1177/1758835919838958 pmid: 31019568
[21]	Umeda S, Kanda M, Koike M, et al. Copine 5 expression predicts prognosis following curative resection of esophageal squamous cell carcinoma[J]. Oncol Rep, 2018,40(6):3772-3780. DOI: 10.3892/or.2018.6742. doi: 10.3892/or.2018.6742 pmid: 30272363
[22]	Liu L, Zhang S, Liu X, et al. Aberrant promoter 2 methylation mediated downregulation of protein tyrosine phosphatase, non receptor type 6, is associated with progression of esophageal squamous cell carcinoma[J]. Mol Med Rep, 2019,19(4):3273-3282. DOI: 10.3892/mmr.2019.9971. doi: 10.3892/mmr.2019.9971 pmid: 30816454
[23]	Guo X, Zhao L, Shen Y, et al. Polymorphism of miRNA and eso-phageal cancer risk: an updated systemic review and meta-analysis[J]. Onco Targets Ther, 2019,12:3565-3580. DOI: 10.2147/OTT.S193958. doi: 10.2147/OTT.S193958 pmid: 31213825
[24]	Li H, Diao S, Li J, et al. An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk[J]. Oncotarget, 2017,8(17):28888-28896. DOI: 10.18632/oncotarget.16322. doi: 10.18632/oncotarget.16322 pmid: 28415817
[25]	Wang X, An D, Liu X, et al. MicroRNA-27a downregulates the expression of Hsp90 and enhances the radiosensitivity in esophageal squamous cell carcinoma[J]. Onco Targets Ther, 2019,12:5967-5977. DOI: 10.2147/OTT.S197456. doi: 10.2147/OTT.S197456 pmid: 31413593
[26]	Lin J, Liu Z, Liao S, et al. Elevation of long non-coding RNA GAS5 and knockdown of microRNA-21 up-regulate RECK expression to enhance esophageal squamous cell carcinoma cell radio-sensitivity after radiotherapy[J]. Genomics, 2020,112(3):2173-2185. DOI: 10.1016/j.ygeno.2019.12.013. doi: 10.1016/j.ygeno.2019.12.013 pmid: 31866421
[27]	Cao T, Shen J, Pan W, et al. Upregulation of long noncoding RNA ANRIL correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma[J]. J BUON, 2018,23(6):1862-1866. pmid: 30610814
[28]	Liu B, Sun X. miR-25 promotes invasion of human non-small cell lung cancer via CDH1[J]. Bioengineered, 2019,10(1):271-281. DOI: 10.1080/21655979.2019.1632668. doi: 10.1080/21655979.2019.1632668 pmid: 31208279
[29]	Hu XX, Feng J, Huang XW, et al. Histone deacetylases up-regulate C/EBPα expression through reduction of miR-124-3p and miR-25 in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2019,514(3):1009-1016. DOI: 10.1016/j.bbrc.2019.05.024. doi: 10.1016/j.bbrc.2019.05.024 pmid: 31092334
[30]	Liu B, Li X, Li C, et al. miR-25 mediates metastasis and epithelial-mesenchymal-transition in human esophageal squamous cell carcinoma via regulation of E-cadherin signaling[J]. Bioengineered, 2019,10(1):679-688. DOI: 10.1080/21655979.2019.1687391. doi: 10.1080/21655979.2019.1687391 pmid: 31679450